We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Different D-Dimer Values Compared for Venous Thromboembolism Risk

By LabMedica International staff writers
Posted on 27 Sep 2015
D-dimer assays are generally evaluated according to cutoff points calibrated for of venous thromboembolism (VTE) exclusion and used to estimate the individual risk of recurrence after a first idiopathic event VTE.

The increase in age-dependent D-dimer levels has long been seen as a problem for the use of these assays in the work-up for VTE exclusion, and the assays performs poorly in the elderly population when traditional cutoff levels are adopted. More...
Different cutoff systems have therefore been proposed and prospectively investigated to rule out pulmonary embolism.

Scientist at the University Hospital of Bologna (Italy) and their colleagues screened a total of 1,010 patients, whose index VTE event was idiopathic or associated with weak risk factors, and were included in the management protocol. Persistently negative D-dimer results were recorded in 528 patients (52.8%) who permanently interrupted anticoagulation and were followed up for a maximum of two years. In contrast, the remaining 482 patients had positive D-dimer results, and at the moment of their first positive result, were recommended to continue or resume anticoagulant therapy and followed by their anticoagulation clinic.

D-dimer levels were measured using the following commercial quantitative assays: VIDAS D-dimer Exclusion (bioMerieux; Lyon, France), Innovance D-DIMER (Siemens; Deerfield, IL, USA), HemosIL D-dimer HS or HemosIL D-dimer (Instrumentation Laboratory; Milan, Italy), and (v) STA Liatest D-dimer (DiagnosticaStago; Asnieres-sur-Seine, France). As cutoff values for negative/positive results, the centers used those specific for the assay, distinguishing those with results expressed as fibrinogen equivalent units (FEU) or non-FEU (D-dimer units) and for age and gender.

The predetermined cutoff levels for each assay, specific for age (lower in subjects less than 70 years), and gender (because it is lower in males), were used. In young subjects, the D-dimer-ULtrasonography in Combination Italian Study (DULCIS) low cutoff levels resulted in half the recurrent events that would have occurred using the other criteria. In elderly patients the DULCIS results were similar to those calculated for the two age-adjusted criteria. The adoption of traditional VTE exclusion criteria would have led to positive results in the large majority of elderly subjects without a significant reduction in the rate of recurrent event.

The authors concluded that the low cutoff levels adopted in the DULCIS study for young subjects resulted in more young patients who resumed anticoagulation with subsequent increased protection from recurrent events in this population that is at high risk of recurrence. In elderly patients, the high DULCIS cutoff points led to results similar to those calculated for the two age-adjusted criteria; the adoption of VTE exclusion criteria would have led to positive results in the large majority of subjects, without a significant reduction in the rate of recurrent event. The study was published on September 12, 2015, in the journal International Journal of Laboratory Hematology.

Related Links:

University Hospital of Bologna
bioMérieux
Siemens



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.